SCHEMBL3006735

SCHEMBL3006735

Cc1ccc(F)cc1S(=O)(=O)N1CCN(c2nc(Cc3ccc(Cl)c(Cl)c3)cs2)CC1

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CNR1 P21554 3/20 0.43
CNR2 P34972 3/20 0.43
ALDH1A1 P00352 4/20 0.42
SMN1; SMN2 Q16637 4/20 0.42
L3MBTL1 Q9Y468 3/20 0.42
LMNA P02545 4/20 0.41
RAB9A P51151 4/20 0.41
MAPT P10636 2/20 0.41
MEN1 O00255 1/20 0.41
KMT2A Q03164 1/20 0.41
MAPK1 P28482 2/20 0.40
USP2 O75604 2/20 0.39
RECQL P46063 1/20 0.39
HSD17B10 Q99714 1/20 0.39
HTT P42858 2/20 0.37
THRB P10828 1/20 0.37
TSHR P16473 1/20 0.37
HSD11B1 P28845 1/20 0.37
DCTPP1 Q9H773 1/20 0.36
CYP3A4 P08684 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3652889 0.97 CNR1 (0.41) CNR1CNR2ALDH1A1SMN1; SMN2L3MBTL1
SCHEMBL3653659 0.94 ALDH1A1 (0.41) CNR1CNR2ALDH1A1SMN1; SMN2L3MBTL1
SCHEMBL3009882 0.94 CNR1 (0.42) CNR1CNR2ALDH1A1SMN1; SMN2L3MBTL1
SCHEMBL3019142 0.92 ALDH1A1 (0.42) CNR1CNR2ALDH1A1SMN1; SMN2L3MBTL1
SCHEMBL3020823 0.92 ALDH1A1 (0.44) CNR1CNR2ALDH1A1SMN1; SMN2L3MBTL1
SCHEMBL3006749 0.90 SMN1; SMN2 (0.42) CNR1CNR2ALDH1A1SMN1; SMN2L3MBTL1
SCHEMBL3005942 0.90 ALDH1A1 (0.42) CNR1CNR2ALDH1A1SMN1; SMN2L3MBTL1
SCHEMBL3652946 0.90 CNR1 (0.42) CNR1CNR2ALDH1A1SMN1; SMN2L3MBTL1
SCHEMBL3008281 0.90 SMN1; SMN2 (0.44) CNR1CNR2ALDH1A1SMN1; SMN2L3MBTL1
SCHEMBL3014483 0.90 ALDH1A1 (0.44) ALDH1A1SMN1; SMN2L3MBTL1LMNAMAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2188272-B1 PHENYL- AND BENZYLTHIAZOLYLPIPERAZINE DERIVATIVES FOR THE TREATMENT OF NEURODEGENERATIVE DISEASES REMYND NV (BE) 2016-02-24 EP disclosed
US-8722681-B2 N-sulfonyl thiazolylpiperazine derivatives and related N-sulfonyl heterocyclic derivatives for the treatment of neuro degenerative diseases NV REMYND (BE) 2014-05-13 US disclosed
US-20100197703-A1 N-SULFONYL THIAZOLYLPIPERAZINE DERIVATIVES AND RELATED N-SULFONYL HETEROCYCLIC DERIVATIVES FOR THE TREATMENT OF NEURO DEGENERATIVE DISEASES NV REMYND (BE) 2010-08-05 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100197703-A1 N-SULFONYL THIAZOLYLPIPERAZINE DERIVATIVES AND RELATED N-SULFONYL HETEROCYCLIC DERIVATIVES FOR THE TREATMENT OF NEURO DEGENERATIVE DISEASES SMN1; SMN2, HTT, SNCA CNR1 3069/4885CNR2 2911/4885ALDH1A1 3510/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.